Table 1.
Characteristics of Mutational Subtypes in UTUC.
| Characteristic | Total | Hyper | TP53/MDM2 | RAS | FGFR3 | TN |
|---|---|---|---|---|---|---|
| Number | 199 | 11 | 75 | 30 | 70 | 13 |
| Gender – no. (%) | ||||||
| Male | 139 (69.8) | 6 (54.5) | 49 (65.3) | 23 (76.7) | 51 (72.9) | 10 (76.9) |
| Female | 60 (30.2) | 5 (45.5) | 26 (34.7) | 7 (23.3) | 19 (27.1) | 3 (23.1) |
| Age at surgery | ||||||
| Median | 71.9±9.5 | 72.2±5.8 | 71.4±9.4 | 65.0±10.1 | 74.4±9.7 | 71.2±7.3 |
| Range | 41–90 | 59–78 | 53–90 | 48–86 | 41–86 | 61–84 |
| T -category – no. (%) | ||||||
| Non–invasive | 98 (49.2) | 8 (72.7) | 15 (20.0) | 19 (63.3) | 53 (75.7) | 4 (30.8) |
| Invasive | 101 (50.8) | 3 (27.3) | 60 (80.0) | 11 (36.7) | 17 (24.3) | 9 (69.2) |
| Grade – no. (%) | ||||||
| Low | 90 (45.2) | 5 (45.5) | 10 (13.3) | 13 (43.3) | 57 (81.4) | 5 (38.5) |
| High | 109 (54.8) | 6 (54.5) | 65 (86.7) | 17 (56.7) | 13 (18.6) | 8 (61.5) |
| Morphology – no. (%) | ||||||
| Papillary | 169 (84.9) | 11 (100.0) | 52 (69.3) | 28 (93.3) | 70 (100.0) | 8 (61.5) |
| Non–papillary | 30 (15.1) | 0 (0.0) | 23 (30.7) | 2 (6.7) | 0 (0.0) | 5 (38.5) |
| UBC history – no. (%) | ||||||
| Previous | 18 (9.0) | 0 (0.0) | 10 (13.3) | 1 (3.3) | 4 (5.7) | 6 (46.2) |
| Simultaneous | 16 (8.0) | 1 (9.1) | 9 (12.0) | 0 (0.0) | 6 (8.6) | 0 (0.0) |
| None | 165 (83.0) | 10 (90.9) | 56 (74.7) | 29 (96.7) | 60 (85.7) | 7 (53.8) |
| Squamous differentiation – no. (%) | ||||||
| + | 23 (11.6) | 0 (0.0) | 13 (17.3) | 5 (16.7) | 2 (2.9) | 2 (15.4) |
| − | 176 (88.4) | 11 (100.0) | 62 (82.7) | 25 (83.3) | 68 (97.1) | 11 (84.6) |
| Metastasis – no. (%) | ||||||
| + | 52 (26.1) | 0 (0.0) | 33 (44.0) | 6 (20.0) | 7 (10.0) | 4 (30.8) |
| − | 147 (73.9) | 11 (100.0) | 42 (56.0) | 24 (80.0) | 63 (90.0) | 9 (69.2) |
| Tumor location – no. (%) | ||||||
| Pelvis | 123 (61.8) | 2 (18.2) | 29 (38.7) | 30 (100.0) | 53 (75.7) | 9 (69.2) |
| Ureter | 65 (32.7) | 8 (72.7) | 38 (50.6) | 0 (0.0) | 15 (21.4) | 4 (30.8) |
| Unknown | 11 (5.5) | 1 (9.1) | 8 (10.7) | 0 (0.0) | 2 (2.9) | 0 (0.0) |
| Tobacco history – no. (%) | ||||||
| + | 93 (46.7) | 3 (27.3) | 29 (38.7) | 18 (60.0) | 39 (55.7) | 5 (38.5) |
| − | 106 (53.3) | 8 (72.7) | 46 (61.3) | 12 (40.0) | 31 (44.3) | 8 (61.5) |
| Chemotherapy – no. (%) | ||||||
| AC | 56 (28.1) | 1 (9.1) | 33 (44.0) | 4 (13.3) | 10 (14.3) | 5 (38.5) |
Hyper, hypermutated; TP53/MDM2, TP53/MDM2-mutated; RAS, RAS-mutated; FGFR3, FGFR3-mutated, TN, triple-negative; UBC, urothelial bladder carcinoma; AC, adjuvant chemotherapy.